Method for preparing oxadiazine intermediates for killing arthropods
By using phosgene or phosgene derivatives in combination with a phase transfer catalyst and a basic base in the absence of organic bases and metal hydrides, the safety risks and environmental impacts of the preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate in the prior art have been solved, and efficient intermediate preparation has been achieved.
Patent Information
- Application Number
- CN202280049071.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-07-13
- Filing Date
- 2022-07-11
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-07-11
AI Technical Summary
Existing technologies for preparing oxadiazine intermediates that kill arthropods pose safety risks and environmental impacts due to the use of sodium hydride and amine bases, and lack efficient methods to shorten the conversion process.
Methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate was prepared by a shortened method using phosgene or phosgene derivatives in the presence of a phase transfer catalyst, an alkaline base, and a hydrocarbon organic solvent, avoiding the use of organic bases and metal hydrides.
A safe and economical method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate was achieved, reducing the environmental impact of waste disposal and improving preparation efficiency.
Smart Images

Figure CN117940402B_ABST
Abstract
Description
Technical fields:
[0001] This invention relates to a method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate, a key intermediate for the preparation of indoxacarb, in the absence of organic bases and metal hydrides. Background technology:
[0002] Previously, patent applications WO 9211249, WO 95 / 29171, and WO 9319045 disclosed oxadiazines for killing arthropods and corresponding synthetic methods for preparing bioactive oxadiazines and their intermediates. Specifically, WO 95 / 29171 disclosed the preparation of the key intermediate methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate using sodium hydride in mineral oil and glycol dimethyl ether. Furthermore, IN 241255 claims the preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate using sodium hydride in aromatic solvents and ethers. Additionally, IN 240984 claims the preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate from the corresponding methyl carbamate with triphosgene or diphosgene in the presence of an organic amine and an aromatic solvent.
[0003] However, the use of sodium hydride or similar metal hydrides in large-scale commercial production is disadvantageous for safety reasons. On the other hand, the use of amine bases in large-scale commercial methods has significant environmental and human health impacts. Amine waste generated by these methods must be treated before it is exposed to the environment. Furthermore, publication IPCOM000262804D describes the preparation of a methyl (4-(trifluoromethoxy)phenyl)carbamate precursor using phosgene, dimethyl carbonate, and methanol; however, it does not disclose the further conversion of this precursor into the final methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate of formula I via a telescopic conversion.
[0004] Based on the above, the aforementioned preparation method still needs improvement for safe and economical commercial operation. In particular, there is a need for a more efficient method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate of Formula I, which is an intermediate in the preparation of indoxacarb, an arthropod culprit. Summary of the Invention:
[0005] This invention provides a method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having Formula I.
[0006]
[0007] The method involves reacting a compound having formula (IV) with phosgene or a phosgene derivative in the presence of a phase-transfer catalyst, a basic base, and a hydrocarbon organic solvent, and in the absence of an organic base and a metal hydride.
[0008]
[0009] Furthermore, the present invention provides a shortening method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I.
[0010]
[0011] The method includes:
[0012] a) Preparation of compounds having formula (II)
[0013]
[0014] By reacting a compound having formula (III) with phosgene or phosgene derivatives in the presence of dimethyl carbonate and a hydrocarbon organic solvent.
[0015]
[0016] b) To prepare a compound of formula (IV) by reacting a compound of formula (II) with methanol and distilling off dimethyl carbonate.
[0017]
[0018] c) Reacting a compound having formula (IV) with phosgene or phosgene derivatives in the presence of a phase transfer catalyst, a basic base, and a hydrocarbon organic solvent.
[0019] The present invention further provides a method for preparing indoxacarb having formula V.
[0020]
[0021] This method uses methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate of formula (I) prepared by a method comprising the following steps: reacting a compound of formula (IV) with phosgene in the presence of a phase-transfer catalyst, an alkaline base and a hydrocarbon organic solvent, and in the absence of an organic base and a metal hydride.
[0022] manual:
[0023] definition:
[0024] Before elaborating on this topic in detail, it may be helpful to provide definitions for certain terms used herein. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this topic pertains.
[0025] Unless otherwise specified, the term "a / an" as used herein includes both the singular and the plural. Therefore, the terms "a / an" or "at least one" are used interchangeably in this application.
[0026] Throughout this application, the description of different embodiments uses the term "comprising"; however, those skilled in the art will understand that in certain specific cases, the language of "substantially consisting of" or "consisting of" may be used instead to describe embodiments.
[0027] For the purpose of better understanding this teaching, and in no way limiting its scope, all figures and other numerical values used in the specification and claims to express quantities, percentages or proportions shall be understood to be modified with the term “about” in all cases, unless otherwise indicated.
[0028] Therefore, unless otherwise specified, the numerical parameters listed in the following description and appended claims are approximate values that may vary depending on the desired characteristics sought to be obtained. At a minimum, each numerical parameter should be interpreted according to the number of significant figures reported and by applying common rounding techniques. In this regard, the use of the term "about" herein specifically includes ±10% of the indicated value within the range. Furthermore, the endpoints of all ranges relating to the same component or characteristic herein include endpoints that are independently combinable and include all intermediate points and ranges.
[0029] Certain compounds of the present invention can exist as one or more stereoisomers. Various stereoisomers include enantiomers, diastereomers, and geometric isomers. Those skilled in the art will understand that a stereoisomer may be more active and / or may exhibit beneficial effects when enriched relative to one or more other stereoisomers, or when separated from one or more other stereoisomers. Furthermore, those skilled in the art know how to separate, enrich, and / or selectively prepare said stereoisomers.
[0030] Therefore, the compounds of the present invention can exist as a mixture of stereoisomers, as individual stereoisomers, or as an optically active form.
[0031] As used herein, the term "shortening method" refers to carrying out several reactions without the need for separation of intermediate products. In particular, a shortening method indicates the performance of multiple transformations (including reaction quenching and other post-processing operations) without the need for direct separation of intermediates. The shortened solution of the intermediate can be extracted, filtered (provided the desired product remains in the filtrate), and subjected to solvent exchange, but the intermediate ultimately remains in solution and continues to undergo subsequent transformations.
[0032] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference in their entirety, to the extent that each individual publication, patent or patent application is specifically and individually indicated as incorporated herein by reference.
[0033] This invention provides a technique for the successful and convenient preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate of formula (I) as an intermediate for the synthesis of indoxacarb having formula V, in the absence of organic bases and metal hydrides.
[0034] According to embodiments, the present invention relates to a method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I.
[0035]
[0036] The method involves reacting a compound having formula (IV) with phosgene or a phosgene derivative in the presence of a phase-transfer catalyst, a basic base, and a hydrocarbon organic solvent, and in the absence of an organic base and a metal hydride.
[0037]
[0038] In the embodiments, the phosgene derivatives are selected from diphosgene, triphosgene, or mixtures thereof.
[0039] In some embodiments, a method “in the absence of an organic base” means a method in which each mole of methyl carbamate having formula (IV) contains no more than 0.01 moles of an organic base.
[0040] In some embodiments, a method “in the absence of an organic base” means a method in which each mole of methyl carbamate having formula (IV) contains no more than 0.05 moles of an organic base.
[0041] In some embodiments, a method “in the absence of an organic base” means a method in which each mole of methyl carbamate having formula (IV) contains no more than 0.1 moles of an organic base.
[0042] In some embodiments, a method “in the absence of a metal hydride” means a method in which each mole of methyl carbamate having formula (IV) contains no more than 0.01 moles of a metal hydride.
[0043] In some embodiments, a method “in the absence of a metal hydride” means a method in which each mole of methyl carbamate having formula (IV) contains no more than 0.05 moles of a metal hydride.
[0044] In some embodiments, a method “in the absence of a metal hydride” means a method in which each mole of methyl carbamate having formula (IV) contains no more than 0.1 moles of a metal hydride.
[0045] According to some embodiments, the method is suitable for use in hydrocarbon organic solvents such as hexane, petroleum ether, toluene, chlorobenzene, xylene, mesitylene, and mixtures thereof.
[0046] In such embodiments, the method is carried out in chlorobenzene.
[0047] According to some embodiments, the method involves alkaline bases such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, and mixtures thereof.
[0048] In such embodiments, the method involves the presence of sodium hydroxide, potassium hydroxide, or a mixture thereof.
[0049] According to some embodiments, the amount of basic base used in the method is 1.0 to 10.0 moles relative to 1 mole of methyl carbamate having formula (IV).
[0050] According to some embodiments, the amount of sodium hydroxide base used in this method is 6.0 moles relative to 1 mole of methyl carbamate having formula (IV).
[0051] In some embodiments, the method involves the presence of a phase transfer catalyst such as tetrabutylammonium iodide, tetraethylammonium bromide, tetramethylammonium bromide, tetrapropylammonium bromide, tetrabutylammonium bromide, crown ether, PEG, and mixtures thereof.
[0052] According to some embodiments, the amount of phase transfer catalyst used in this method is 0.001 to 0.1 mol relative to 1 mol of methyl carbamate having formula (IV).
[0053] According to some embodiments, the amount of phase transfer catalyst used in this method is 0.05 moles relative to 1 mole of methyl carbamate having formula (IV).
[0054] In such embodiments, the phase transfer catalyst is tetrabutylammonium bromide (TBAB).
[0055] According to another embodiment, the compound having formula (II) is not separated from the reaction mixture.
[0056] The desired product, a compound having formula I, can be separated by methods known to those skilled in the art, including crystallization, extraction, and distillation.
[0057] According to embodiments, the present invention relates to a shortening method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I.
[0058]
[0059] The method includes:
[0060] a) Preparation of compounds having formula (II)
[0061]
[0062] By reacting a compound having formula (III) with phosgene or phosgene derivatives in the presence of dimethyl carbonate and a hydrocarbon organic solvent.
[0063]
[0064] b) To prepare a compound of formula (IV) by reacting a compound of formula (II) with methanol and distilling off dimethyl carbonate.
[0065]
[0066] c) Reacting a compound having formula (IV) with phosgene or phosgene derivatives in the presence of a phase transfer catalyst, a basic base, and a hydrocarbon organic solvent.
[0067] In such embodiments, the hydrocarbon organic solvent is selected from the group consisting of toluene, chlorobenzene, xylene, mesitylene, and mixtures thereof.
[0068] According to some embodiments, the preparation of compounds having formula (II) is carried out at a temperature of 10°C to 70°C.
[0069] In such embodiments, the preparation of compounds having formula (II) is carried out at a temperature of 25°C to 70°C.
[0070] In such embodiments, the preparation of compounds having formula (II) is carried out at a temperature of 35°C.
[0071] According to some embodiments, the method includes dimethyl carbonate / chlorobenzene in a molar ratio of 0.0:1.0 to 0.84:1.0.
[0072] In another embodiment, the preparation of the compound having formula (III) was carried out at a temperature of 10°C to 70°C.
[0073] In another embodiment, the preparation of the compound having formula (IV) is carried out at a temperature of 0°C to 80°C.
[0074] In another embodiment, the preparation of the compound having formula (I) was carried out at a temperature of 0°C to 80°C.
[0075] In some other embodiments, the present invention relates to the preparation of indoxacarb having formula V.
[0076]
[0077] This preparation uses methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I.
[0078]
[0079] The methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I is prepared by reacting a compound having formula (IV) with phosgene or a phosgene derivative in the presence of a phase transfer catalyst, an alkaline base and a hydrocarbon organic solvent, and in the absence of an organic base and a metal hydride, as described in the previous examples.
[0080] The desired product, a compound having formula V, can be separated by methods known to those skilled in the art, including crystallization, extraction, and distillation.
[0081] In some other embodiments, the present invention relates to the preparation of indoxacarb having formula V.
[0082]
[0083] The preparation uses methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I.
[0084]
[0085] The methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having Formula I is prepared by a shortening method, which includes:
[0086] a) Preparation of compounds having formula (II)
[0087]
[0088] By reacting a compound having formula (III) with phosgene in the presence of dimethyl carbonate and a hydrocarbon organic solvent.
[0089]
[0090] b) To prepare a compound of formula (IV) by reacting a compound of formula (II) with methanol and distilling off dimethyl carbonate.
[0091]
[0092] c) Reacting a compound having formula (IV) with phosgene or a phosgene derivative in the presence of a phase transfer catalyst, a basic base, and a hydrocarbon organic solvent, as described in the previous examples.
[0093] The desired product, a compound having formula I, can be separated by methods known to those skilled in the art, including crystallization, extraction, and distillation.
[0094] This disclosure is further illustrated by referring to certain embodiments described herein, and by the following examples of the preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I, and compounds having formulas (II), (IV), and (V) in detail. It will be apparent to those skilled in the art that many modifications can be made to both the materials and methods without departing from the scope of this disclosure. Further embodiments will become apparent to those skilled in the art based on considerations of the specification.
[0095] Example:
[0096] Example 1: Preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate (Method A)
[0097] 11 g of chlorobenzene and 0.05 g (0.15 mmol) of TBAB were placed in a three-necked flask equipped with a stirrer. Then, over a period of 1 h at 25 °C, 14.3 g (0.09 mol) of a 25% NaOH aqueous solution and 3.5 g (0.015 mol) of methyl carbamate of formula (IV) with 2.94 g (0.01 mol) of triphosgene in 38.5 g of chlorobenzene were added dropwise to the reaction mixture, followed by stirring for another 5 minutes. Then, 50 mL of a 10% HCl aqueous solution was added, and the organic phase was separated and washed with another 50 mL of a 10% HCl aqueous solution. The organic phase was then concentrated under reduced pressure (10 mbar at 40 °C) to give 4.1 g of the product (86% yield).
[0098] Example 2: Continuous flow preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate (Method B)
[0099] For continuous flow experiments, a typical setup consists of two syringe pumps followed by a micromixer, which is then connected to a coiled PFA tube (0.8 mm inner diameter, 3.65 mL volume). Residence time is varied by changing the flow rate. Samples are collected in an acidic solution to quench the reaction at the outlet of the reaction tube. The products are analyzed after further dilution.
[0100] 3.5 g (0.015 mol) of methyl carbamate of formula (IV), 2.94 g (0.01 mol) of triphosgene, and 0.05 g (0.15 mmol) of TBAB were dissolved in 50 g of chlorobenzene, and 3.6 g of NaOH was dissolved in 11 mL of water. The two reaction solutions were mixed using a T-type micromixer, followed by residence time in a tube. The process was carried out at 25 °C. The residence time in the tube was maintained at 5 minutes. The reaction mixture was then washed with a 10% aqueous HCl solution, the organic phase was separated, and concentrated under reduced pressure (10 mbar at 40 °C) to give 0.5 g of the product (98% yield).
[0101] Example 3: Continuous flow preparation of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate (Method B)
[0102] For continuous flow experiments, a typical setup consists of two syringe pumps followed by a micromixer, which is then connected to a coiled PFA tube (0.8 mm inner diameter, 3.65 mL volume). Residence time is varied by changing the flow rate. Samples are collected in an acidic solution to quench the reaction at the outlet of the reaction tube. The products are analyzed after further dilution.
[0103] 3.5 g (0.015 mol) of methyl carbamate of formula (IV), 10.9 g (0.01 mol) of a 27% phosgene solution in MCB, and 0.05 g (0.15 mmol) of TBAB were dissolved in 50 g of chlorobenzene, and 3.6 g of NaOH was dissolved in 11 mL of water. The two reaction solutions were mixed using a T-type micromixer, and then a residence time tube was used. The process was carried out at 25 °C. The residence time in the tube was maintained at 5 min. Subsequently, the reaction mixture was washed with a 10% aqueous HCl solution, the organic phase was separated, and concentrated under reduced pressure (10 mbar at 40 °C) to give 0.38 g of product (74% yield).
Claims
1. A method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I: (I) The method comprises reacting a compound having formula (IV) with phosgene, diphosgene, or triphosgene in the presence of a phase transfer catalyst, a basic base, and an organic solvent. (IV), in, The phase transfer catalyst is selected from the group consisting of tetrabutylammonium iodide, tetraethylammonium bromide, tetramethylammonium bromide, tetrapropylammonium bromide, tetrabutylammonium bromide, crown ethers, PEG, and mixtures thereof; The alkaline base is selected from the group consisting of sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, and mixtures thereof; and The organic solvent is selected from the group consisting of hexane, petroleum ether, toluene, chlorobenzene, xylene, mesitylene, and mixtures thereof. The method described herein is carried out in the absence of organic bases and metal hydrides.
2. The method according to claim 1, wherein, The phase transfer catalyst is tetrabutylammonium bromide (TBAB).
3. The method according to claim 1, wherein, The compound having formula (IV) is not separated from the reaction mixture.
4. A shortened method for preparing methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate having formula I (I) The method includes: a) To prepare a compound of formula (II) by reacting a compound of formula (III) with phosgene in the presence of dimethyl carbonate and an organic solvent. (II) (III) b) To prepare a compound of formula (IV) by reacting a compound of formula (II) with methanol and distilling off dimethyl carbonate. (IV) c) Reacting a compound having formula (IV) with phosgene in the presence of a phase-transfer catalyst, a basic base, and an organic solvent, wherein the phase-transfer catalyst is selected from the group consisting of tetrabutylammonium iodide, tetraethylammonium bromide, tetramethylammonium bromide, tetrapropylammonium bromide, tetrabutylammonium bromide, crown ethers, PEG, and mixtures thereof; the basic base is selected from the group consisting of sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, and mixtures thereof; and the organic solvent is selected from the group consisting of hexane, petroleum ether, toluene, chlorobenzene, xylene, mesitylene, and mixtures thereof.
5. The method according to claim 4, wherein, The preparation of the compound having formula (II) is carried out at a temperature of 10°C to 70°C.
6. The method according to claim 4, comprising a dimethyl carbonate / organic solvent in a ratio of 0.0:1.0 to 0.84:1.0, wherein the organic solvent is selected from the group consisting of hexane, petroleum ether, toluene, chlorobenzene, xylene, mesitylene, and mixtures thereof.
7. The method according to claim 6, wherein the organic solvent is chlorobenzene.
8. The method according to claim 4, wherein, The preparation of the compound having formula (III) is carried out at a temperature of 10°C to 70°C.
9. The method according to claim 4, wherein, The preparation of the compound having formula (IV) is carried out at a temperature of 0°C to 80°C.
10. The method according to claim 1, wherein, The preparation of the compound having formula (I) is carried out at a temperature of 0°C to 80°C.
11. A method for preparing indoxacarb having formula V (V) The method includes preparing a compound having formula (I) according to any one of claims 1-4.
Citation Information
Patent Citations
Arthropodicidal carboxanilides
WO1992011249A1
Arthropodicidal amides
WO1993019045A1
Preparation of arthropodicidal oxadiazines
WO1995029171A1
